Furthermore, this paradox is also present in patients with melanoma in whom the immune score did not reflect any significant difference between high or low expression of ANTXR1. However, patients had a longer survival probability (Figure 2C) when patients with low expression of ANTXR1 were treated with immunotherapy. This evidence concerns the gene ANTXR1 and melanoma.